5Kobayashi H,Takazawa K,Matsumoto C,et al.The role of intravenous coronary thrombolysis for patients with acute myocardial infarction in different treatment strategies[J].Intern Med,2006,45(11):709.
6Smalling RW,Bode C,Kalbfleish J,et al.More rapid,complete,and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction:RAPID Investigators[J].Circulation,1995,91:2725-2732.
7Cohen M,Demer C,Gurfinkel EP,et al.A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease.Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group[J].N Engl J Med,1997,337:447-452.
8Antman EM,McCabe CH,Gurfinkel EP,et al.Enoxaparin prevents death and cardiac ischemic events in unstable angina /non-Q-wave myocardial infarction.Results of the thrombolysis in myocardial infarction (TIMI)ⅡB trial[J].Circulation,1999,100(15):1593-1601.
9Serebruany VL,Malin AI,Callahan KP,et al.Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction:the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy[J].Am Heart J,2003,145(4):636-642.
10Assessment of the Safety and Efficacy of a New Thrombolytic Regimen(ASSENT)-3 Investigators.Efficacy and safety of tenecteplase in combination with enoxaparin,abciximab,or unfractionated heparin:the ASSENT-3 randomised trial in acute myocardial infarction[J].Lancet,2001,358:605-613.
